Collegium Pharmaceutical to Buy AZSTARYS for $650M, Expanding ADHD Franchise Through 2037

Collegium Pharmaceutical logo 5 Hot Stocks With Summer Buybacks You Can Cash In On Collegium Pharmaceutical (NASDAQ:COLL) outlined plans to acquire the ADHD drug AZSTARYS and related corporate subsidiaries from Corium Therapeutics, a transaction the company said would add a second commercial-stage ADHD product alongside Jornay PM and extend the durability of its ADHD revenue base. Transaction terms and timing On the investor call, President and CEO Vikram Karnani said Collegium plans to pay $650 mi ...